home / stock / cgtx / cgtx news

CGTX News and Press, Cognition Therapeutics Inc. From 04/19/23

Stock Information
Company Name: Cognition Therapeutics Inc.
Stock Symbol: CGTX
Market: NASDAQ
Website: cogrx.com
Menu
CGTX CGTX Quote CGTX Short CGTX News CGTX Articles CGTX Message Board
Get CGTX Alerts

News, Short Squeeze, Breakout and More Instantly...
CGTX - Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) will be presenting in vitro results characterizing the role of sigma-2 (σ-2) receptors and effect of CT1812 in cell-based models of dry age-related macular degeneration (AMD). CT18...
CGTX - Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases

NEW YORK, April 12, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) announced that a review article titled, “Sigma-2 Receptors – From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases” ( doi.org/1...

CGTX - Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer's Disease Processes

NEW YORK, March 28, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) presented results of a meta-analysis from the first cohort (SHINE-A) of 24 participants in the Phase 2 SHINE (COG0201; NCT03507790 ) and the complete dataset from the Phase 1b SPA...

CGTX - Cognition Therapeutics Announces New Episode of "Conversations" Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies

PURCHASE, N.Y., March 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”) has released its fourth “Conversations” video podcast, a two-part conversation about dementia with Lewy bodies (DLB) focusing...
CGTX - Catalyst watch: Eyes on Deutsche Bank, Intel, Virgin Orbit and the Fed's favorite inflation gauge

2023-03-24 15:00:32 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...

CGTX - Cognition Therapeutics, Inc. (CGTX) Q4 2022 Earnings Call Transcript

2023-03-23 09:26:10 ET Cognition Therapeutics, Inc. (CGTX) Q4 2022 Earnings Conference Call March 23, 2023 08:00 AM ET Company Participants Daniel Kontoh-Boateng - Investor Relations Lisa Ricciardi - President and Chief Executive Officer Andrew Einhorn - Interim ...

CGTX - Cognition Therapeutics GAAP EPS of -$0.91 misses by $0.68

2023-03-23 07:48:42 ET Cognition Therapeutics press release ( NASDAQ: CGTX ): Q4 GAAP EPS of -$0.91 misses by $0.68 . On December 31, 2022, the company’s cash balance was $41.6 million. The company estimates that it has sufficient cash to fund operations and...
CGTX - Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update

- Completed enrollment of CT1812 Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease - Received FDA clearance for Phase 2 START Study of CT1812 in early Alzheimer’s disease - Received FDA clearance for IND for Phase 2 study of CT1812 in 240 patients with geo...

CGTX - Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer's Disease at AD/PD 2023

NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX) will be presenting results of a proteomic biomarker meta-analysis of cerebrospinal fluid, or CSF, samples from the initial cohort of participants in the Phase 2 SHINE (COG0201; NCT0...

CGTX - UPDATE - Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results

PURCHASE, N.Y., March 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the Company will release financia...
Previous 10 Next 10